Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France (PARROTFISH)

Alfasigma

Status: Active, not recruiting

Conditions: Rheumatoid Arthritis

Treatments: Drug: Filgotinib

Study type: Observational

Funder types: Industry

Identifiers

NCT05323591

GLPG0634-CL-424

49028 (Other Identifier)

Details and patient eligibility

About

An observational study to describe the effectiveness, safety, and patient-reported outcomes (PROs) in participants with moderate to severe active rheumatoid arthritis (RA) in France receiving filgotinib in real-world setting.

Enrollment: 155 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants aged ≥18 years with a diagnosis of moderate to severe active RA being prescribed filgotinib in accordance with the local treatment practices and product label for the first time.
• Female participants of childbearing potential must agree to use contraception while taking filgotinib as per product label.
• Participants must be willing and able to use an electronic device to complete the study PROs.
• Participant must sign and date the Informed Consent Form (ICF) before enrollment into the study.

Exclusion criteria

• Participation in any interventional or non-interventional study without prior approval from the Medical Lead. This does not preclude inclusion of participants enrolled to national registries.
• Female participant is pregnant or intending to become pregnant while taking filgotinib.

Trial design

155 participants in 1 patient group

Filgotinib

Description:

Participants will receive treatment for moderate to severe active RA with at least one dose of filgotinib in accordance with the product label.

Treatment:

Drug: Filgotinib